PainChek Limited (ASX: PCK) aims to provide innovative pain assessment products and services to people in pain. The focus is to improve the quality of life for the pain inflicted utilizing AI and face recognition technology. PCK’s tool, PainChek®, is the world’s first pain assessment tool and monitoring device with regulatory clearance in Europe and Australia. The company provides carers throughout the numerous clinical regions.
The PainChek® app can be enabled on smartphones and it is rapidly growing in the healthcare sector. Also, last year the company won the UK Tech Rocketship Award for ‘Tech for an Ageing society’.
The app captures a video of the patient, analyses it in real time and detects presence of facial micro-expressions for signs of pain using facial recognition software. Pain severity score is further calculated after combining expressions to other pain indicators.
PainChek® Technology (Source: Company’s report)
On 27th May 2019, PCK announced that PainChek® had taken its first leap in the international market via a distribution agreement with Person Centred Software, provider of Mobile Care Monitoring, a mobile solution for evidencing care interactions, electronic care planning, reporting and analysis. As agreed, Person Centred Software would issue the PainChek Application to its United Kingdom customers via its sales and marketing engine. The pricing would be in sync with the Australian pricing model.
As per the company’s quarterly release for Q1 2019 period, PCK experienced a positive sales quarter. Also, the Morrison Government would make an investment of $5 million to have the PainChek® app in aged care centres of Australia region.
B2B Australian sales and market development (Source: Company’s report)
The cash flow for the Q1 2019, highlights are explained in the table below:
By the close of day on 31st May 2019, the stock closed at A$0.160, up by 6.667%, compared to its last close.
Biotron Limited (ASX: BIT) is a clinical stage biotechnology player, based in Sydney, Australia. It focusses on the growth and commercialisation of a small molecule method which is capable to treat various serious viral diseases. The technology targets viroporin proteins, which are the main elements to enable the pathogenicity of viruses. These are inclusive of HIV-1, Zika, hepatitis C, Influenza, Respiratory Syncytial Virus and Dengue.
At present, BIT’s primary compound, BIT225 is undergoing the Phase 2 development. It would be utilized for the treatment of hepatitis C and HIV-1 viruses.
Advancement towards eradicating HIV?1 infection (Source: Company’s report)
The below table summarises the company’s Quarterly report released for Q1 2019:
|Cash Flow||Amount ($A’000)|
|Net cash used in operating activities||(572)|
|Net cash used in investing activities||(4)|
|Net cash from financing activities||21|
|Cash and cash equivalents at the end of Q1 2019||6,441|
|Estimated cash outflows for next quarter||624|
BIT’s H119 report highlighted the release of positive human clinical data from its BIT225-009 Phase 2 trial of BIT225, which had a profound impact on the virus source. Besides this, the company was evaluating the activity of its compound library for activity against Hepatitis B virus.
On the financial end, BIT incurred a Total comprehensive loss of $261,133. Whereas, the loss in pcp (31st December 2017) was $159,799. The total assets of the company were valued at $7,117,240. The total liabilities held were $377,238. BIT’s total equity amounted to $6,740,002.
By the close of day on 31st May 2019, the stock closed at A$0.068. In the past 6 months, the stock has generated a negative return of 55.48%, though its 1-year return stands better at 245.00%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.